Drug Trial Radar · NCT04576156
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
327
Actual
Start
Apr 12, 2021
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Geron CorporationIndustry
- Sponsor type
- Industry
- First posted
- Oct 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
Conditions
- Myelofibrosis
Interventions
ImetelstatDrug
Imetelstat sodium will be given intravenously at 9.4 mg/kg every 21 days, until disease progression or unacceptable toxicity, treatment discontinuation or study end.
Best Available Therapy (BAT)Drug
Non-JAK-inhibitor treatment will be given, which may include but is not limited to hydroxyurea, thalidomide or an analog of thalidomide, interferon, danazol, hypomethylating agents, chemotherapy or radiotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Baseline (Day 1) until End of Study (EOS) (approximately 3 years )]
Locations
144 sites in 26 countries. Site status is shown where the registry gives one.
University of California-San Diego/Moores UCSD Cancer Center
La Jolla, California
UCLA David Geffen School of Medicine
Los Angeles, California
Smilow Cancer Center at YNHH
New Haven, Connecticut
BRCR Medical Center Inc
Plantation, Florida
University of South Florida
Tampa, Florida
Norton Cancer Institute
Louisville, Kentucky
Icahn School of Medicine at Mount Sinai
New York, New York
Duke University Medical Center
Durham, North Carolina
Gabrail Cancer Center
Canton, Ohio
Prairie Lakes Health Care System, Inc.
Watertown, South Dakota
The University of Texas MD
Houston, Texas
Northwest Medical Specialties PLLC
Seattle, Washington
Sanatorio Allende
Córdoba, Argentina
Hospital Aleman
Ciudad de Buenos Aires, Buenos Aires, Argentina
Sanatorio de la Mujer
Rosario, Santa Fe Province, Argentina
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Epworth Healthcare
Richmond, Victoria, Australia
Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhügel
Wein, Burgenland, Austria
Krankenhaus der Elisabethinen
Linz, Upper Austria, Austria
Kepler Universitätsklinikum Gm
Linz, Upper Austria, Austria
Klinikum Wels-Grieskirchen GmbH
Wels, Upper Austria, Austria
Universitair Ziekenhuis Brussel - Myeloom Centrum Brussel (MCB)
Jette, Belgium
AZ Klina
Antwerp, Antwerpen, Belgium
UZ Antwerpen
Edegem, Antwerpen, Belgium
Centre Hospitalier de Jolimont
Haine-Saint-Paul, Hainaut, Belgium
Universitair Ziekenhuis Gent
Ghent, Oost-Vlaanderen, Belgium
CEPON Centro de Pesquisas Oncologicas SC
Florianópolis, Brazil
Hospital A.C.Camargo Cancer Center - Clinical Oncology
São Paulo, Brazil
Centro de oncologia Leonardo da Vinci
Fortaleza, Ceará, Brazil
Hospital das Clínicas UFG
Goiânia, Goiás, Brazil
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil
Hospital de Clinicas de Porto Alegre - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa LTDA
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Israelita Albert Einstein
São Paulo, São Paulo, Brazil
Fundacao Doutor Amaral Carvalho / Hospital Amaral Carvalho
São Paulo, São Paulo, Brazil
UMBAL Sveti Georgi
Plovdiv, Plovdiv, Bulgaria
Specialized Hospital for Active Therapy of Hematological dis
Sofia, Sofia, Bulgaria
Hospital Pablo Tobon Uribe
Antioquia, Colombia
Showing 40 of 144 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.